Executive
Summary
VENENO’s Challenge:
What Is the “Future Plan” Moving Forward?
Solving global challenges
Deep-tech startups
Veneno Technologies is a deep-tech startup spun off from the National Institute of Advanced Industrial Science and Technology (AIST). (The first venture certified by AIST Solutions Co., Ltd.)
We are developing platform technologies that transform highly bioactive peptides found in nature (DRPs) into safe, industrially viable forms for use in pharmaceuticals and biomaterials.
Leveraging our proprietary platform, Veneno Suite™, we are advancing real‑world implementation across drug discovery, agrochemicals, and animal health.
Monetizing through drug discovery and biomaterials
Drug Discovery
Business
We primarily conduct joint research with pharmaceutical companies to develop and out-license our pipeline. Our approach is expected to create a new class of drug candidates that fills the “missing middle” between small‑molecule drugs and antibody therapeutics.
Bio-materials
Business
Within the field of bio-manufacturing, we are prioritizing the development of DRP additives (defensins) for the animal health sector, and launching an on-demand DRP reagent business for research use.
Growth Roadmap and Milestones
Aiming for an IPO in 2029
Advancing R&D Capabilities through Series A Financing
We plan to use the Series A round to further enhance our platform technology, accelerate collaborative research, expand patent landscaping activities, strengthen management and business development functions, and scale up our laboratory operations.
Preparing for Global Expansion through Series B Financing
We plan to increase the number of collaborative research agreements with pharmaceutical companies and other partners, advance R&D for DRP as a biomaterial, and build scalable production facilities for mass manufacturing.
Achieving Operating Profitability
We will drive rapid growth toward commercialization not only in agriculture, animal health, and food, but also across broader applications, with the goal of achieving operating profitability and establishing a solid revenue base.
Achieving an IPO
Establishing an International Presence
We are committed to achieving an IPO in 2029. Beyond that, our goal is to establish overseas subsidiaries and accelerate the full-scale expansion of our global business.
Advancing R&D Capabilities through Series A Financing
We plan to use the Series A round to further enhance our platform technology, accelerate collaborative research, expand patent landscaping activities, strengthen management and business development functions, and scale up our laboratory operations.
sPreparing for Global Expansion through Series B Financing
We plan to increase the number of collaborative research agreements with pharmaceutical companies and other partners, advance R&D for DRP as a biomaterial, and build scalable production facilities for mass manufacturing.
Achieving Operating Profitability
We will drive rapid growth toward commercialization not only in agriculture, animal health, and food, but also across broader applications, with the goal of achieving operating profitability and establishing a solid revenue base.
Achieving an IPO
Establishing an International Presence
We are committed to achieving an IPO in 2029. Beyond that, our goal is to establish overseas subsidiaries and accelerate the full-scale expansion of our global business.
Post-IPO Strategy
Global Expansion of the Drug Discovery Business
We will drive the global expansion of our drug discovery business, focusing primarily on the United States. By establishing local subsidiaries, strengthening our clinical development framework, and deepening partnerships with leading research institutions in key hubs such as Boston and San Francisco, we aim to accelerate our global growth.
Building an International Presence for the Biomaterials Business
With global expansion as a core premise of our biomaterials business, we plan to establish subsidiaries in key markets. While keeping our headquarters in Japan, we will steadily expand our operational footprint overseas.
Expanding the Revenue Model through Veneno Suite™
Our proprietary platform, Veneno Suite™, is designed to accelerate revenue generation through licensing partnerships and fee-for-service offerings. As we advance the market rollout of our products, we also see strong potential in milestone-based revenue, royalties, and the launch of biomaterial products.
Equity Story
Our goal is to build Veneno into a global biotech company with a market capitalization reaching the hundreds of billions of yen.
Our goal in the drug discovery business is to enter into three new strategic partnerships with pharmaceutical companies each fiscal year from the end of 2027 fiscal year (June 2027) onward. In addition, in the agriculture and biochemical fields, we plan to establish two new business partnerships each fiscal year and achieve profitability across our platform business as a whole by the end of fiscal year 2028. Through these initiatives, we will build a solid foundation for a successful IPO.
With two core business domains, drug discovery and biomaterials, we aim to achieve sustainable growth and expand revenue. Our target is to complete an IPO by the end of fiscal year 2029, which will mark our ninth fiscal year.
Partnership
Extensive Partnerships
We promote joint research and business development in collaboration with a diverse range of companies, academic institutions, and other partners.
Drug Discovery Business
Addressing Target Proteins That Are Difficult to Drug with Small Molecules or Antibodies
In preclinical development, while some companies are seeking effective peptide therapeutics, very few are advancing discovery in a systematic way with a specialized technological focus.
As one of the few early players in this field, we have established distinctive strengths that set us apart. In the drug discovery space, although there are several companies working on specialized peptide therapeutics, our proprietary platform, Veneno Suite™, enables a decisive advantage in both discovery speed and quality.
Biomaterials Business
Developing Environmentally Friendly Crop Protection Solutions
In the agricultural sector, multinational companies and startups developing bio-based crop protection products are entering the market. However, we have established a pioneering position in the application of this technology.
As demand continues to grow and expectations rise for products with new modes of action, we are expanding the market from a position of clear competitive strength.
Partners
DRP
Global Platform
A Global Market Worth Tens of Trillions of Yen
Building the World’s Only Global Platform Powered by DRP and Scalable Manufacturing
A High-Growth Market Gaining Global Attention Next-Generation Modality: Peptide Therapeutics
Peptide therapeutics, a next-generation modality, are attracting strong global attention and are shaping a market worth tens of trillions of yen worldwide.
In the crop protection market, demand is measured in the trillions of yen, with growing interest in biological pesticides and products with novel modes of action. Meanwhile, the animal health market continues to grow steadily, driven by the aging pet population and increasing demand for livestock disease prevention.
3 STRENGTH
当社における3つの強み
Unparalleled Discovery Capabilities Powered by a Proprietary Drug Discovery Platform
By leveraging our proprietary DRP drug discovery platform, Veneno Suite™, we can efficiently identify a wide range of peptide candidates that have been difficult to discover using conventional methods. This allows us to generate optimized peptides for specific targets in a short time frame, dramatically improving the likelihood of success in drug discovery. In the rapidly emerging field of peptide therapeutics as a next-generation modality, we have established a technological edge that is highly difficult for competitors to replicate.
Proprietary Manufacturing Technology Enabling Cost-Efficient, Scalable Production
We have developed a proprietary manufacturing technology called the Super Secrete Method, which makes it possible to mass-produce high-quality peptides at significantly lower cost than conventional synthesis approaches. This allows us to reduce development costs while accelerating commercialization, resulting in a strong competitive advantage. The technology is especially compelling not only for pharmaceuticals, but also for the crop protection and animal health sectors, where cost efficiency is essential.
Diversified Growth through Technology Expansion Across Multiple Markets
Our technology has applications beyond pharmaceuticals, encompassing crop protection and animal health. This multi-market applicability enables us to diversify risk through our business portfolio rather than depending on a single market. At the same time, cross-sector applications of our technology generate synergies that create new market opportunities and broaden our growth potential.
Driving Innovation Together
Intractable Diseases, Antimicrobial Resistance, and Food Security
We look forward to your support as partners in creating meaningful social impact through our technology and business.
Social Impact
Veneno’s Social Impact
Providing New Therapeutic Options for Intractable Diseases
Pharmaceutical companies’ strategic pipelines increasingly target severe and intractable diseases such as pulmonary hypertension, psoriasis, cancer, autoimmune diseases, heart failure, and glaucoma, where existing treatments often remain insufficient. The most important social value of our work is its potential to offer new options to patients living with unmet medical needs. With market projections through 2040 reaching tens to hundreds of billions of dollars, the potential impact is substantial both in commercial terms and in the number of patients who could be benefited.
Addressing Infectious Diseases and Public Health Challenges
Pharmaceutical development pipelines also include efforts to tackle major global threats posed by drug-resistant pathogens, including MRSA and NTM infections. These are urgent public health challenges, and advancing solutions in this area contributes directly to stronger action against antimicrobial resistance (AMR).
Reducing the Burden of Healthcare Costs and Improving Efficiency
By leveraging our proprietary DRP mass-production technology, we can reduce the manufacturing cost of pharmaceuticals and, in turn, help contain the cost of treatment. In an era of increasingly expensive advanced medical care, this can support more equitable access to healthcare while also contributing to the long-term sustainability of social security systems and healthcare financing.
Expanding Impact Across Animal Health and Food Safety
Beyond human therapeutics, our technology can also be applied in agriculture and animal health. This creates value in areas such as treatment options for aging pets, preventing livestock disease to support food security while reducing antibiotic use, and enabling low-environmental-impact agricultural and livestock development that advances sustainable agriculture.
In this way, we contribute to society through a One Health approach that links people, animals, and the environment.
Helping Reduce Global Health Disparities
While addressing large global markets, our cost advantage also supports the potential for adoption in emerging markets and regions with limited healthcare resources. This gives our technology the potential to help reduce healthcare disparities between developed and emerging countries.